Novocure Ltd (NVCR)
Novocure Ltd operates in the Medical - Devices industry of the Healthcare sector, headquartered in Baar, CH. The stock last traded at $17.42, down 1.39% on the session, giving a market capitalisation of $2.03B. On trailing twelve-month figures it carries a trailing P/E of -13.40, a net margin of -21.2%. Its beta of 0.98 implies it has historically moved less than the broad market.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Novocure Ltd is most often compared with the following Healthcare names: